Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 20/20 | 0.77 |
| ▸ | SYK | P43405 | 8/20 | 0.77 |
| ▸ | IRAK1 | P51617 | 7/20 | 0.72 |
| ▸ | AURKA | O14965 | 1/20 | 0.65 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.65 |
| ▸ | FLT3 | P36888 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL357448 | 0.87 | IRAK4 (1.00) | IRAK4SYKIRAK1AURKAMAP3K7 | |
| SCHEMBL357835 | 0.86 | IRAK4 (1.00) | IRAK4SYKIRAK1AURKAMAP3K7 | |
| SCHEMBL359209 | 0.86 | IRAK4 (1.00) | IRAK4SYKIRAK1AURKAMAP3K7 | |
| SCHEMBL360455 | 0.86 | IRAK4 (0.91) | IRAK4SYKIRAK1AURKAMAP3K7 | |
| SCHEMBL358800 | 0.84 | IRAK4 (1.00) | IRAK4SYKIRAK1AURKAMAP3K7 | |
| SCHEMBL358757 | 0.84 | IRAK4 (0.86) | IRAK4SYKIRAK1AURKAMAP3K7 | |
| SCHEMBL358918 | 0.83 | IRAK4 (1.00) | IRAK4SYKIRAK1AURKAMAP3K7 | |
| SCHEMBL358947 | 0.83 | IRAK4 (1.00) | IRAK4SYKIRAK1AURKAMAP3K7 | |
| SCHEMBL358163 | 0.83 | IRAK4 (1.00) | IRAK4SYKIRAK1AURKAMAP3K7 | |
| SCHEMBL358260 | 0.82 | IRAK4 (1.00) | IRAK4SYKIRAK1AURKAMAP3K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015962-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | ARORA NIDHI (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015962-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK4, IRAK1, IRAK2 | IRAK4 1/4885SYK 634/4885IRAK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.